22nd Century Group Inc (XXII)

[damaniac311]

Every time I look at Chardan's valuation of XXII and their price target...it always comes with the language of red sun and magic reaching revenues of $142 million and $55 million respectively by 2023 as part of their "sum of the parts" estimate. It also includes X-22 out there on the market. Right now they're still looking for a pharmaceutical partner for phase 3 for X-22. So all this talk of why Chardan hasn't budged on their target seems odd to me, because I read it as it should at least be $9 by 2023. So to not change up a PT that's several years away doesn't seem strange at all IMO. Maybe I'm reading this all wrong though, and I'd welcome a correction in thinking.